Ocugen (OCGN) News Today $0.71 -0.01 (-0.70%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical TrialJanuary 18 at 10:50 AM | msn.comBreakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis PigmentosaJanuary 17, 2025 | msn.comOcugen announces first patient dosed in Phase 1 OCU200 trial for DMEJanuary 16, 2025 | markets.businessinsider.comOcugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular EdemaJanuary 16, 2025 | globenewswire.comOcugen reports ‘positive’ update from Phase 1/2 OCU400 trialJanuary 13, 2025 | markets.businessinsider.comOcugen’s OCU400: Promising Clinical Efficacy and Strong Buy Rating Amidst Valuation and Safety ConfidenceJanuary 13, 2025 | markets.businessinsider.comOcugen's (OCGN) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Ocugen in a research note on Monday.January 13, 2025 | marketbeat.comOcugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis PigmentosaJanuary 13, 2025 | globenewswire.comOcugen, Inc. (NASDAQ:OCGN) Shares Acquired by State Street CorpState Street Corp lifted its holdings in shares of Ocugen, Inc. (NASDAQ:OCGN - Free Report) by 7.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,824,517 shares of the company's stock after purchasing an additional 1December 25, 2024 | marketbeat.comOcugen’s Gene Therapy Trial for Dry AMD AdvancesDecember 21, 2024 | msn.comOcugen’s Phase 1/2 study of OCU410 approved for continuation by DSMBDecember 19, 2024 | markets.businessinsider.comData and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationDecember 19, 2024 | globenewswire.comOcugen to Present at Oppenheimer Movers in Rare Disease SummitDecember 11, 2024 | msn.comOcugen CEO to Present at Oppenheimer Movers in Rare Disease SummitDecember 11, 2024 | globenewswire.comOcugen Inc. stock rises Friday, still underperforms marketDecember 6, 2024 | marketwatch.comOcugen, Inc. to Present at NobleCon20 Emerging Growth Equity ConferenceDecember 1, 2024 | msn.comOcugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity ConferenceNovember 28, 2024 | finance.yahoo.comOcugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity ConferenceNovember 27, 2024 | globenewswire.comOcugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease TreatmentNovember 22, 2024 | msn.comOcugen announces EMA granted orphan medicinal product designation for OCU410STNovember 21, 2024 | markets.businessinsider.comOcugen Reports Promising Results from OCU410 ArMaDa Trial for Geographic AtrophyNovember 21, 2024 | msn.comOcugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt DiseaseNovember 20, 2024 | globenewswire.comOcugen reports positive data for OCU400, OCU410November 19, 2024 | msn.comOcugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trialNovember 19, 2024 | markets.businessinsider.comOcugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationNovember 19, 2024 | globenewswire.comOcugen Appoints Ramesh Ramachandran as Financial OfficerNovember 16, 2024 | markets.businessinsider.comWall Street Expects These 2 Under-the-Radar Growth Stocks to OutperformNovember 16, 2024 | msn.comOcugen’s Promising Pipeline and Strategic Advances Support Buy RatingNovember 16, 2024 | markets.businessinsider.comOcugen’s Gene Therapies Show Promising Results: Analyst Recommends BuyNovember 14, 2024 | markets.businessinsider.comHC Wainwright Has Negative Outlook of Ocugen FY2024 EarningsOcugen, Inc. (NASDAQ:OCGN - Free Report) - Equities researchers at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Ocugen in a note issued to investors on Monday, November 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.18) per shaNovember 14, 2024 | marketbeat.comOcugen’s Promising Gene Therapy Advancements and Financial Stability Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comOcugen to Present Innovations at Nasdaq Clinical ShowcaseNovember 13, 2024 | markets.businessinsider.comOcugen’s Strong Financial Management and Promising Gene Therapy Pipeline Drive Buy RatingNovember 11, 2024 | markets.businessinsider.comOcugen (NASDAQ:OCGN) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Ocugen in a research note on Monday.November 11, 2024 | marketbeat.comChardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN)Chardan Capital reissued a "buy" rating and set a $6.00 price objective on shares of Ocugen in a research report on Friday.November 11, 2024 | marketbeat.comOcugen, Inc. (NASDAQ:OCGN) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comOcugen: Progress in Gene Therapy and Financial OutlookNovember 9, 2024 | markets.businessinsider.comOcugen secures $30M debt fundingNovember 8, 2024 | msn.comOcugen Provides Business Update with Third Quarter 2024 Financial ResultsNovember 8, 2024 | globenewswire.comOcugen Secures $30 Million in Debt FundingNovember 7, 2024 | globenewswire.comThose who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%November 1, 2024 | finance.yahoo.comOcugen (OCGN) Set to Announce Quarterly Earnings on FridayOcugen (NASDAQ:OCGN) will be releasing earnings before the market opens on Friday, November 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=636742)November 1, 2024 | marketbeat.comPromising Developments in Ocugen’s Pipeline Support Buy RatingOctober 31, 2024 | markets.businessinsider.comOcugen to Spotlight Gene Therapy Advances at Upcoming Clinical ShowcaseOctober 31, 2024 | msn.comOcugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024October 28, 2024 | globenewswire.comOcugen Advances Stargardt Disease Trial with Promising Gene TherapyOctober 24, 2024 | msn.comOcugen’s Promising Pipeline and Valuation Propel Buy RatingOctober 24, 2024 | markets.businessinsider.comOcugen announces DSMB for OCU410ST trial approved enrollment for second phaseOctober 23, 2024 | markets.businessinsider.comData and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt DiseaseOctober 22, 2024 | globenewswire.comOcugen Announces Third Quarter Financial Results Conference CallOctober 18, 2024 | msn.com Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address OCGN Media Mentions By Week OCGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCGN News Sentiment▼0.260.44▲Average Medical News Sentiment OCGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCGN Articles This Week▼65▲OCGN Articles Average Week Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ArriVent BioPharma News Tyra Biosciences News Avid Bioservices News Anavex Life Sciences News Cronos Group News Septerna News Avadel Pharmaceuticals News Relay Therapeutics News Prothena News CorMedix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCGN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
